DESIPRAMINE HYDROCHLORIDE- desipramine hydrochloride tablet, film coated

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

DESIPRAMINE HYDROCHLORIDE (UNII: 1Y58DO4MY1) (DESIPRAMINE - UNII:TG537D343B)

Available from:

CorePharma, LLC

INN (International Name):

DESIPRAMINE HYDROCHLORIDE

Composition:

DESIPRAMINE HYDROCHLORIDE 10 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Desipramine hydrochloride tablets, USP are indicated for the treatment of depression. The use of MAOIs intended to treat psychiatric disorders with desipramine hydrochloride or within 14 days of stopping treatment with desipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. The use of desipramine hydrochloride within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS  and DOSAGE AND ADMINISTRATION). Starting desipramine hydrochloride in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS  and DOSAGE AND ADMINISTRATION). Desipramine hydrochloride is contraindicated in the acute recovery period following myocardial infarction. It should not be used in those who have shown prior hypersensitivity to the drug. Cross-sensitivity between this and other dibenzazepines is a possibility.

Product summary:

10 mg white to off-white, round “film coated” tablets debossed CP on one side and 10 on the other side       Bottles of 100           (NDC 64720-415-10) 25 mg white to off-white, round “film coated” tablets debossed CP over 25 on one side and plain on the other side Bottles of 100           (NDC 64720-416-10) 50 mg white to off-white, round “film coated” tablets debossed CP over 50 on one side and plain on the other side Bottles of 100           (NDC 64720-417-10) 75 mg white to off-white, round “film coated” tablets debossed CP over 75 on one side and plain on the other side Bottles of 100           (NDC 64720-418-10) 100 mg white to off-white, round “film coated” tablets debossed CP over 100 on one side and plain on the other side Bottles of 100           (NDC 64720-419-10) 150 mg white to off-white, round “film coated” tablets debossed CP over 150 on one side and plain on the other side Bottles of 50             (NDC 64720-420-05) Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from excessive heat. Dispense in tight container.

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

                                DESIPRAMINE HYDROCHLORIDE- DESIPRAMINE HYDROCHLORIDE TABLET, FILM
COATED
CorePharma, LLC
----------
MEDICATION GUIDE
DESIPRAMINE HYDROCHLORIDE TABLETS, USP
(DES IP' RA MEEN HYE" DROE KLOR' IDE)
ANTIDEPRESSANT MEDICINES, DEPRESSION AND OTHER
SERIOUS MENTAL ILLNESSES, AND SUIDICAL THOUGHTS
OR ACTIONS
Read the Medication Guide that comes with your, or your family
member's, antidepressant medicine. This
Medication Guide is only about the risk of suicidal thoughts and
actions with antidepressant medicines.
Talk to your, or your family member's, healthcare provider about:
•
all risks and benefits of treatment with antidepressant medicines
•
all treatment choices for depression or other serious mental illness
What is the most important information I should know about
antidepressant medicines, depression and
other serious mental illnesses, and suicidal thoughts or actions?
1. Antidepressant medicines may increase suicidal thoughts or actions
in some children, teenagers,
and young adults within the first few months of treatment.
2. Depression and other serious mental illnesses are the most
important causes of suicidal thoughts
and actions. Some people may have a particularly high risk of having
suicidal thoughts or actions. These
include people who have (or have a family history of) bipolar illness
(also called manic-depressive
illness) or suicidal thoughts or actions.
3. How can I watch for and try to prevent suicidal thoughts and
actions in myself or a family
member?
•
Pay close attention to any changes, especially sudden changes, in
mood, behaviors, thoughts, or
feelings. This is very important when an antidepressant medicine is
started or when the dose is
changed.
•
Call the healthcare provider right away to report new or sudden
changes in mood, behavior,
thoughts, or feelings.
•
Keep all follow-up visits with the healthcare provider as scheduled.
Call the healthcare provider
between visits as needed, especially if you have concerns about
symptoms.
Who should not take desipramine hydrochloride?
•
You shoul
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                DESIPRAMINE HYDROCHLORIDE- DESIPRAMINE HYDROCHLORIDE TABLET, FILM
COATED
COREPHARMA, LLC
----------
DESIPRAMINE HYDROCHLORIDE TABLETS, USP
10 MG, 25 MG, 50 MG, 75 MG, 100 MG AND 150 MG
RX ONLY
SUICIDALITY AND ANTIDEPRESSANT DRUGS
ANTIDEPRESSANTS INCREASED THE RISK COMPARED TO PLACEBO OF SUICIDAL
THINKING AND BEHAVIOR
(SUICIDALITY) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS IN SHORT-TERM
STUDIES OF MAJOR
DEPRESSIVE DISORDER (MDD) AND OTHER PSYCHIATRIC DISORDERS. ANYONE
CONSIDERING THE USE OF
DESIPRAMINE HYDROCHLORIDE OR ANY OTHER ANTIDEPRESSANT IN A CHILD,
ADOLESCENT, OR YOUNG
ADULT MUST BALANCE THIS RISK WITH THE CLINICAL NEED. SHORT-TERM
STUDIES DID NOT SHOW AN
INCREASE IN THE RISK OF SUICIDALITY WITH ANTIDEPRESSANTS COMPARED TO
PLACEBO IN ADULTS
BEYOND AGE 24; THERE WAS A REDUCTION IN RISK WITH ANTIDEPRESSANTS
COMPARED TO PLACEBO IN
ADULTS AGED 65 AND OLDER. DEPRESSION AND CERTAIN OTHER PSYCHIATRIC
DISORDERS ARE
THEMSELVES ASSOCIATED WITH INCREASES IN THE RISK OF SUICIDE. PATIENTS
OF ALL AGES WHO ARE
STARTED ON ANTIDEPRESSANT THERAPY SHOULD BE MONITORED APPROPRIATELY
AND OBSERVED CLOSELY
FOR CLINICAL WORSENING, SUICIDALITY, OR UNUSUAL CHANGES IN BEHAVIOR.
FAMILIES AND CAREGIVERS
SHOULD BE ADVISED OF THE NEED FOR CLOSE OBSERVATION AND COMMUNICATION
WITH THE PRESCRIBER.
DESIPRAMINE HYDROCHLORIDE IS NOT APPROVED FOR USE IN PEDIATRIC
PATIENTS. (SEE WARNINGS:
CLINICAL WORSENING AND SUICIDE RISK, PRECAUTIONS: INFORMATION FOR
PATIENTS, AND
PRECAUTIONS: PEDIATRIC USE.)
DESCRIPTION
Desipramine hydrochloride, USP is an antidepressant drug of the
tricyclic type, and is chemically: 5_H_-
Dibenz[_bƒ_]azepine-5-propanamine,10,11-dihydro-_N_-methyl-,
monohydrochloride.
INACTIVE INGREDIENTS
The following inactive ingredients are contained in all dosage
strengths: microcrystalline cellulose,
colloidal silicon dioxide, lactose monohydrate, povidone,
croscarmellose sodium, magnesium stearate,
titanium dioxide, hypromellose, polyethylene glycol, and polysorbate
80.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Available evidence sugg
                                
                                Read the complete document
                                
                            

Search alerts related to this product